article thumbnail

Precision Biosciences gets grant for engineered meganucleases for modifying human mitochondrial dna

Pharmaceutical Technology

Discover how this mitochondria-targeting engineered meganuclease is revolutionizing genetic research. Unlock the potential of genetic modification with Precision Biosciences Inc's patented MTEM technology for precise editing of eukaryotic cells.

Engineer 195
article thumbnail

Synlogic gets grant for genetically engineered bacteria for attenuating metabolic diseases

Pharmaceutical Technology

Discover how Synlogic Inc's patented genetically engineered bacteria produce short-chain fatty acids to combat metabolic diseases. Learn more about this innovative treatment approach.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Samsung Biologics, GreenLight conclude Covid-19 vaccine engineering run

Pharmaceutical Technology

Samsung Biologics and GreenLight Biosciences have completed the initial commercial-scale engineering run for their messenger ribonucleic acid (mRNA) Covid-19 vaccine under their manufacturing collaboration. The post Samsung Biologics, GreenLight conclude Covid-19 vaccine engineering run appeared first on Pharmaceutical Technology.

Engineer 262
article thumbnail

Yield10 Bioscience gets grant for genetically engineered oilseed plant expressing plant protein

Pharmaceutical Technology

Discover the groundbreaking patent by Yield10 Bioscience Inc for a genetically engineered oilseed plant expressing a plant protein, revolutionizing biotechnology in agriculture.

article thumbnail

Interferon alfa-2b by Center for Genetic Engineering and Biotechnology for Genital Warts (Condylomata Acuminata): Likelihood of Approval

Pharmaceutical Technology

Interferon alfa-2b is under clinical development by Center for Genetic Engineering and Biotechnology and currently in Phase II for Genital Warts (Condylomata Acuminata).

article thumbnail

Cellectis files patent for engineered T-cells for immunotherapy with inhibited B2M expression

Pharmaceutical Technology

Discover Cellectis SA's groundbreaking patent for engineered T-cells designed for immunotherapy, targeting cancer, infections, and autoimmune diseases. Learn about the innovative method and composition outlined in the patent for effective and affordable treatment.

Engineer 130
article thumbnail

FDA signs off on Adaptimmune's Tecelra as the first engineered cell therapy for a solid tumor

Fierce Pharma

Adaptimmune has won accelerated FDA approval | Adaptimmune has won accelerated FDA approval for Tecelra (afami-cel), a treatment for metastatic or unresectable synovial sarcoma which becomes the first engineered cell therapy for a solid tumor and the first new treatment in the indication in more than a decade.

Engineer 132